Category: Urology / Nephrology

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.The study, presented at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

At the start of Kidney Wales Foundation’s four month campaign to improve Kidney services in Wales Jenny Randerson AM , Welsh Liberal Democrat Health Spokesperson has stated her full support for their work. She said: “The Renal National Service Framework critically lacks an action plan and a measurable timetable for action.

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy. The study, at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

For older adults, increased urinary frequency is fairly common. “As people age, in general, the bladder does lose some of its capacity,” says Jonathan M. Vapnek, MD, associate clinical professor of urology at Mount Sinai School of Medicine, according to Mt. Sinai’s Focus on Healthy Aging. “The bladder gets a bit stiffer and therefore, it does not hold as much.

Abbott (NYSE: ABT) announced enrollment of the first patient in HERCULES (Herculink Elite Cobalt Chromium Renal Stent Trial to Demonstrate Efficacy and Safety), a U.S. clinical trial designed to evaluate the safety and effectiveness of the investigational RX Herculink(R) Elite(TM) Renal Stent System to treat patients with renal artery stenosis (RAS), a condition characterized by fatty plaque buildup in the kidney arteries that can lead to high blood pressure.

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, announced that enrollment is complete in its Chemophase(R) Phase I/IIa clinical trial for the treatment of superficial bladder cancer. The Company began dosing patients in this trial in April of last year, following the successful completion of the initial Phase I trial of a single-administration of Chemophase and mitomycin.